ABSTRACT
Motivation Multimorbidity, characterized by the simultaneous occurrence of multiple diseases in an individual, is an increasing global health concern, posing substantial challenges to healthcare systems. Comprehensive understanding of disease-disease interactions and intrinsic mechanisms behind multimorbidity can offer opportunities for innovative prevention strategies, targeted interventions, and personalized treatments. Yet, there exist limited tools and datasets that characterize multimorbidity patterns across different populations. To bridge this gap, we used large-scale electronic health record (EHR) systems to develop the Phenome-wide Multi-Institutional Multimorbidity Explorer (PheMIME), which facilitates research in exploring and comparing multimorbidity patterns among multiple institutions, potentially leading to the discovery of novel and robust disease associations and patterns that are interoperable across different systems and organizations.
Results PheMIME integrates summary statistics from phenome-wide analyses of disease multimorbidities. These are currently derived from three major institutions: Vanderbilt University Medical Center, Mass General Brigham, and the UK Biobank. PheMIME offers interactive exploration of multimorbidity through multi-faceted visualization. Incorporating an enhanced version of associationSubgraphs, PheMIME enables dynamic analysis and inference of disease clusters, promoting the discovery of multimorbidity patterns. Once a disease of interest is selected, the tool generates interactive visualizations and tables that users can delve into multimorbidities or multimorbidity networks within a single system or compare across multiple systems. The utility of PheMIME is demonstrated through a case study on schizophrenia.
Availability and implementation The PheMIME knowledge base and web application are accessible at https://prod.tbilab.org/PheMIME/. A comprehensive tutorial, including a use-case example, is available at https://prod.tbilab.org/PheMIME_supplementary_materials/.
Furthermore, the source code for PheMIME can be freely downloaded from https://github.com/tbilab/PheMIME.
Data availability statement The data underlying this article are available in the article and in its online web application or supplementary material.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NS and YX are supported by the Vanderbilt University Department of Biostatistics Development Award. YX, CB and RH are supported by R21DK127075. YX, DE, EP and DR are supported by P50GM115305. JWS is supported in part by R01 MH118233. The Vanderbilt University Medical Center dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center SD/BioVU, which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141, and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711, and additional funding sources listed at https://victr.vanderbilt.edu/pub/biovu/. This research has been conducted using the UK Biobank Resource under Application Number 43397.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Vanderbilt University Medical Center waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In the revised version, we have made several important updates: 1.Author affiliations have been thoroughly revised and updated. 2.The Funding statement has been amended to include an additional funding source: R01 MH118233. 3.“Massachusetts General Brigham” has been revised to “Mass General Brigham” for clarity and conciseness. 4.The Section of Implementation example has been updated to provide further clarification. Specifically, we have emphasized that the scatter plot can now effectively highlight phecodes that exhibit both high consistency and inconsistency across different institutions.
Data Availability
All data produced in the present work are contained in the manuscript and in its online web application or supplementary material. Sharing of individual level data is restricted. The PheMIME knowledge base and web application are accessible at https://prod.tbilab.org/PheMIME/. A comprehensive tutorial, including a use-case example, is available at https://prod.tbilab.org/PheMIME_supplementary_materials/. Furthermore, the source code for PheMIME can be freely downloaded from https://github.com/tbilab/PheMIME.
https://prod.tbilab.org/PheMIME/
